Symptomatic management in multiple sclerosis

Neurol Clin. 2011 May;29(2):449-63. doi: 10.1016/j.ncl.2011.01.008.


The development of immunomodulatory therapies for multiple sclerosis (MS) has had significant impact in altering the natural history of the disease. Although these agents reduce relapse rate and MRI-associated disease activity, they are only partially effective and do not ameliorate irreversible axonal injury, which produces much of the symptomatic burden of MS. Treatment of MS-associated symptoms remains an essential cornerstone of comprehensive care of patients with MS and, arguably, more favorably enhances quality of life than do the disease-modifying medications. This article reviews strategies of symptom management in patients with MS.

Publication types

  • Review

MeSH terms

  • Cognition Disorders / diagnosis
  • Cognition Disorders / etiology
  • Cognition Disorders / therapy
  • Fatigue
  • Gait Disorders, Neurologic
  • Humans
  • Mood Disorders
  • Multiple Sclerosis / complications*
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / therapy*
  • Muscle Spasticity
  • Pain / diagnosis
  • Sexual Dysfunction, Physiological / diagnosis
  • Sexual Dysfunction, Physiological / etiology
  • Sexual Dysfunction, Physiological / therapy
  • Tremor
  • Urinary Bladder, Neurogenic / diagnosis
  • Urinary Bladder, Neurogenic / etiology
  • Urinary Bladder, Neurogenic / therapy